(Q42638656)

4 November 2017

title

Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting (English)

1 reference

4 November 2017

Barnebey H

1

1 reference

4 November 2017

Kwok SY

series ordinal

2

1 reference

4 November 2017

publication date

1 October 2000

1 reference

4 November 2017

published in

Clinical Therapeutics

1 reference

4 November 2017

volume

22

1 reference

4 November 2017

issue

10

1 reference

4 November 2017

page(s)

1204-1212

1 reference

Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Long-Term Acetazoleamide (Diamox) Administration in Therapy of Glaucomas

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Use of methazolamide (neptazane) in the therapy of glaucoma; comparison with acetazolamide (diamox)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Shall We Count Numbers of Eyes or Numbers of Subjects?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

Effect of changing medication regimens in glaucoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983063-5

1 reference

7 January 2021

10.1016/S0149-2918(00)83063-5

Identifiers

DOI

1 reference

4 November 2017

1 reference